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Abstract 
Objective 
To further analyze calcium tartrate tetrahydrate stones after a recent case report described this 
novel stone. Prior to this, there was only one previously reported occurrence of this stone in a 
human. This unusual stone composition is not tested for routinely. True prevalence and 
possible causes of this stone are unknown. 
Materials/Methods 
During the previous case report, micro-CT and Fourier-transform infrared spectroscopy were 
used to identify a calcium tartrate tetrahydrate stone.  This information was applied to urinary 
stones with previously unidentified compositions in the Mayo Metals laboratory database 
between 2010 and March 2018. Two additional stones were identified at our institution. Three 
patients had medical records available for analysis. 
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Results 
Between 2010 and March 2018, 35 calcium tartrate stones in 25 patients were identified in the 
Mayo database as well as two at our institution (37 stones in 27 patients). Thirty stones were 
pure calcium tartrate with the remainder having elements of more common stones. The 
average age was 46.3 (+/-14.7) with a slightly higher incidence in females (17 vs 10).  
Of the three medical records investigated, all three were males (average age 48.7), and each 
reported consumption of an energy supplement (Spark) routinely.  
Conclusions 
The true prevalence of this relatively unknown stone remains unclear and additional 
investigation is warranted.  We believe all stone laboratories should have access to the IR 
spectra for calcium tartrate tetrahydrate.  Attention should be payed to possible causes of this 
stone, particularly with relation to oral supplements, to aid with future prevention and 
treatment. 
Introduction 
Urolithiasis continues to be a significant clinical issue in both adults and children. Prevalence of 
stone disease has been increasing in the United States and across the globe over the last couple 
of decades. Overall prevalence varies between studies but may range from 7-13%1 in North 
American to 15% or more2 with the most common type of urinary stones in the United States 
being calcium oxalate1. 
We previously reported the finding of a novel kidney stone, calcium tartrate tetrahydrate in a 
young, otherwise healthy male3.  Prior to this finding, there had only been one previously 
recorded calcium tartrate stone in a human being, which involved a stone in Burkina Faso.  
Other than noting the composition of the stone, no additional information (past medical 
history, social history, etc) was available4. 
Calcium tartrate tetrahydrate stones have also been previously described in rat models. In 
these studies, there was an increased prevalence of urolithiasis noted in rats with specific 
purified diets that consisted of dl-choline bitartrate. Infrared spectrum of the formed stones 
was consistent with calcium tartrate tetrahydrate5,6 and was later confirmed by Le Bail et al7. 
In our previous case report3, our patient was noted to consume a large amount of a specific 
dietary supplement that contains L-carnitine (as tartrate) and choline (as bitartrate and citrate), 
raising the question of a possible role of dietary supplementation in formation of this stone. 
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There has been ongoing debate/discussion about the effect of diet and supplements on the 
formation of stone. Formation is known to be asssociated with poor dietary habits, such as 
increased consumption of animal proteins (and decreased fruits and vegetables) and poor fluid 
intake that often consists of high sugar and oxalate beverages2,8,9. Certain supplements and 
vitamins may also play a role in increasing the rate of kidney stones.  In particular, there has 
been significant debate with regards to vitamin C10 and vitamin D11-13 supplementation and 
stone formation.  It is often recommended to avoid high doses, >500-1000mg per day, of 
vitamin C, while recommendations for vitamin D consumption are less clear. There currently 
exists a paucity of data looking at energy supplements and the formation of stones. 
Here, we present findings of additional calcium tartrate tetrahydrate stones, which were 
uncovered by applying the Fourier-transform infrared spectrum of calcium tartrate 
tetrahydrate obtained from our index patient’s stone.  We also try to elucidate any 
commonality between patients diagnosed with this type of stone, specifically with regards to 
social history and possible dietary supplementation. 
Materials/Methods 
The initial finding of a calcium tartrate stone involved stone analysis that revealed a stone of 
unusual composition, which required the stone to be sent for additional examination at Indiana 
University.  Micro CT imaging and Fourier-transform infrared spectroscopy (FT-IR) revealed that 
the majority of the stone material had X-ray attenuation significantly less than that expected of 
calcium oxalate. The infrared (IR) spectrum of the specimen did not match any known 
spectrum, and additional assistance was sought from the laboratory at Tenon Hospital in Paris 
(due to the laboratory having a more extensive database of IR spectra), which eventually 
revealed the identity of the stone to be calcium tartrate tetrahydrate. 
With this new finding, the infrared spectrum that matched the calcium tartrate tetrahydrate 
stone was applied to the Mayo Metals Laboratory, specifically to kidney stones that had 
previously unidentified compositions over the time period of 2010-March 2018. Patient age, 
gender and location were available. In addition, since the index case, an additional calcium 
tartrate tetrahydrate stone was identified at our institution. 
For at least three of the identified calcium tartrate stones (two at Baylor Scott and White and 
one at the Mayo Clinic), patient information was accessible for additional analysis, particularly 
past medical history and social history, in an effort to identify possible etiologies for this type of 
stone. 
Results 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
The initially identified calcium tartrate tetrahydrate stone3 was crystalline with light coloration 
(Figure 1).  Analysis of the micro CT demonstrated intermediate x-ray attenuation, which was 
less than calcium oxalate but higher than that of cystine.  Fourier-transform infrared 
spectroscopy (FT-IR) confirmed the identity of the stone to be calcium tartrate tetrahydrate 
(Figure 2). 
The new spectrum for calcium tartrate tetrahydrate stone was applied to the Mayo Metals 
laboratory database, specifically to stones with previously unidentified spectra. A total of 35 
matching stones were found in 25 different patients. Of the 35 stones, 30 of these were noted 
to be pure calcium tartrate. The remaining stones had compositions that included other more 
common stone types.  One contained uric acid and calcium oxalate monohydrate, one with 
calcium oxalate monohydrate, one with calcium oxalate dihydrate, and one with apatite and 
calcium oxalate monohydrate. 
During the time period from 2010 to March 2018, the first calcium tartrate stone was from 
2012. There was one identified in 2013, fourteen in 2015, ten in 2016, six in 2017 and 3 in 2018 
(January through March). In 2017, approximately 85000 stones were analyzed at the Mayo 
Metals laboratory.  Of those 85000, the composition of only 25 stones was unknown (0.029%).  
When applying the FT-IR spectroscopy of calcium tartrate tetrahydrate to the unidentified 
stones, 6 of the stones were consistent with calcium tartrate tetrahydrate (24% of previously 
unidentified stones). This would suggest an incidence of approximately of 0.007%.  
From the database, the average patient age was 46.3, although the age range varied 
considerably, +/- 14.7 years (oldest 81 and youngest 21).  Seventeen of the patients were 
female, while eight were male.  Stones were sent from across the United States with 16 from 
the Midwest, 2 from the Southeast, 5 from the Northeast and 2 from the West. 
From our institution we added two patients (including our initial patient) with pure calcium 
tartrate tetrahydrate stones (both identified in 2017), bringing the total of identified stones to 
37 in 27 unique patients.  Both patients were male of ages 35 and 59, from the southwest 
(Texas). 
Of the 27 patients with identified calcium tartrate stones, we were able to analyze chart 
information for 3 of them (two at Baylor Scott and White and one at the Mayo Clinic). 
The initial calcium tartrate stone was identified in a 35-year-old male at our institution who 
initially presented with right sided flank pain and was diagnosed with a 2cm non-obstructing 
stone within the right renal pelvis, with average Hounsfield units noted to be 825.  He 
underwent right percutaneous nephrolithotomy. He had no significant past medical history, no 
personal or family history of stone formation and no history of UTIs.  Initial stone analysis 
revealed a 100% ciprofloxacin stone, which prompted additional analysis as the IR spectra was 
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not consistent with ciprofloxacin and clinically did not make sense given the patient’s history. 
The initial lab was unable to identify the stone’s true composition based on the existing 
database. As such, the infrared (IR) spectrum was subsequently sent to the laboratory at Tenon 
Hospital in Paris, which identified the presence of a calcium tartrate tetrahydrate stone3. The 
patient had a 24-hour urinalysis performed, which was largely unremarkable, as the patient had 
an appropriate total volume of urine, 2.97 L, and a pH of 6.5. Specifically, there was no evidence 
of hyperuricemia (555 mg/d), hypocitraturia (484 mg/d), hyperoxaluria (36 mg/d), or 
hypercalciuria (218 mg/d).  Only a mild elevation of urine sodium (216 mEq/d) was present.  It 
was discovered he drank a vitamin/amino acid energy supplement, Spark by AdvoCare, every 
day. He reported drinking “large quantities…4 or more scoops” per day but usually averaged 
about 4. He had been consuming this drink consistently for a little more than a year, but he was 
unable to quantify the exact duration he had been consuming the product. He did continue to 
use the supplement from time of initial stone diagnosis, through the time of his initial 24-hour 
urine collection. 
Our second patient is a 59-year-old male with a history of hyperlipidemia. He initially presented 
to the ED with right sided flank pain and CT scan revealed an 18mm right renal calculus 
involving the right upper pole. He underwent a right PCNL that was noted to be unremarkable 
and patient was stone free after the case. His 24-hour urinalysis, demonstrated several 
abnormalities including high urine pH (7.4), elevated urine sodium (256 mEq/day), and elevated 
urine phosphorous (1463 mg/day). Initial stone analysis showed stone composition of 100% 
calcium oxalate monohydrate (COM).  However, the IR spectrum and gross appearance of the 
stone were not consistent with COM, and on inquiry, he reported drinking 4-5 servings of the 
Spark energy drink supplement every day for greater than a year (exact duration was unable to 
be quantified) prior to his stone episode.  Due to high level of suspicion that the initial stone 
analysis was incorrect, the stone was retested and found to have IR spectrum consistent with 
100% calcium tartrate tetrahydrate. Prior to drinking Spark, the patient had no prior history of 
renal colic.  He continued the supplement until after his post-operative 24-hour urine analysis, a 
There was a third patient identified at the Mayo Clinic.  The patient is a 52-yearold male 
with a 20 year history of stone disease. In the past, he had passed several calcium 
stones and had one previous shock wave lithotripsy (ESWL) and one previous 
ureteroscopic extraction. Over the span of 18 months, he had noted increased 
frequency of stone passage, almost every month. He presented to the ED with right 
flank. CT showed a large burden of stone in the right renal pelvis, and he had a large 
branching stone obstructing in the left proximal ureter, as well as a 2cm bladder stone. 
He had placement of bilateral stents followed by subsequent bilateral PCNL. Analysis of 
stones removed at his procedure showed stones of unknown composition on the right 
side and within the bladder. The left sided stone was noted to be comprised of 70% uric 
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acid and 30% calcium oxalate monohydrate. Unfortunately, a 24-hour urinalysis was 
unavailable for this patient.  Additional inquiry into the patient’s social history revealed 
that he stopped drinking any sugary sodas as part of a weight loss program and was 
successful in losing approximately 45 pounds about 3 years prior to this stone episode. 
Over the past three years, he was drinking AdvoCare energy drinks (specifically Spark). 
He reported drinking two of these every day while driving a truck, 5-7 days per week. 
Discussion 
Until recently, calcium tartrate stones were only described in rat models with specific diets 
containing tartrate (dl-choline bitartrate)5,6,7 and in a single stone patient in Burkina Faso4. We 
were previously able to identify a calcium tartrate stone with use of micro CT and infrared 
spectroscopy3. Unfortunately, this spectrum is not readily available in laboratories that stones 
are sent to for analysis.  As such, the true prevalence of this stone in the population at large is 
unknown.  Using the previously obtained FT-IR spectrum for calcium tartrate, we were able to 
identify calcium tartrate stones amongst stones that previously had unknown composition. This 
spectrum should be available in all stone analysis laboratories to help facilitate further 
identification. Strong consideration should be given to re-analyzing a stone’s composition if 
there is high level of suspicion that the initial stone analysis is incorrect, whether this be from 
discrepancies in the IR spectrum, gross appearance of the stone or from clinical judgment. 
Analysis of the database would also suggest a very low incidence of calcium tartrate 
tetrahydrate stones, ~0.007% based on information from 2017.  While very few stones were 
labeled as unidentified (25 in 2017), a significant number of those, 6 (24%) were later re-labeled 
as calcium tartrate tetrahydrate with the addition of the new FT-IR spectroscopy.  While this 
incidence is low, it may also be inaccurate. Both patients at Baylor Scott and White had 
reported stone compositions that were erroneous (ciprofloxacin and calcium oxalate 
monohydrate) and were only re-tested based due to suspicion that initial analysis was 
incorrect. Unfortunately, the FT-IR spectroscopy of calcium tartrate was only applied to 
unidentified stones, and not all stones that already had identified compositions.   
Evaluation of the Mayo Metals laboratory database showed a vast range of ages for patients 
with this type of stone and there seemed to be a higher rate of women with this type of stone 
(17 female vs 10 male). However, with true prevalence unknown and a relatively small number 
of stones identified, it is difficult to draw accurate conclusions at this time, although the 
prevalence of stone disease, in general, tends to be higher in the male population. 
Unfortunately, of all the identified calcium tartrate only three of the patients (all 3 male) were 
able to be directly questioned with regards to social history, including use of dietary 
supplements. A fourth patient was noted to have no mention of dietary supplements in their 
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chart, but was excluded as the patient was not directly questioned. Interestingly enough, all 
three patients in question reported consuming the same type of supplement, Spark, for 
extended periods of time.  This supplement contains tartrate in the forms of carnitine tartrate, 
L-carnitine, L-tartrate and choline (as bitartrate and citrate). A single serving (one scoop or 
packet) contains 500mg choline and 10mg of L-carnitine (no recommended daily consumption 
established by the FDA). In addition, the supplement, like many others, has significant amount 
of Vitamin C (180mg per serving), which means our three described patients had an intake of 
360-900mg a day from the supplement alone. While many energy supplements contain these 
compounds to some degree, it is unclear to what degree they are absorbed by the GI tract or 
filtered by the kidneys, especially with regards to tartrate. 
Although it is difficult to draw significant conclusions based on a sample size of only three 
patients, these cases suggest that this supplement could be a significant risk factor.  We believe 
this warrants further investigation, and that patients should be inquired about consumption of 
these supplements.  These types of supplements are often used for the purpose of gaining 
muscle mass, energy supplementation and weight loss. 
Conclusion 
We report additional findings of calcium tartrate tetrahydrate stones.  We believe that it would 
be beneficial to include the IR spectra for this unique stone in additional laboratories to 
facilitate its future identification. Repeat stone analysis (either at the initial lab or at more 
specialized labs) should be considered if there is suspicion that the reported composition is 
incorrect. Furthermore, in three patients for which chart information was available and 
supplement intake was discussed, all three reported drinking the energy supplement Spark, 
which contains large amounts of tartrate. While this certainly does not determine causation, we 
believe it would be prudent to inquire about this supplement in additional stone forming 
patients. Additional investigation may prove beneficial in order to help prevent or reduce risk of 
formation of this unique stone. 
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Figures 
 
Figure 1: Photo of stone specimen on mm paper (top), with micro CT image slice (bottom). 
Micro CT slice includes standard specimen composed of pure calcium oxalate (CaOx) 
monohydrate (COM, thick arrow), and apparent CaOx inclusions in the specimen are indicated 
with thin arrow. Arrowheads indicate bulk of specimen, which was verified by infrared 
spectroscopy to be calcium tartrate. 
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Figure 2: Fourier transform infrared (FT-IR) spectrum from the stone original stone specimen 
illustrating calcium tartrate tetrahydrate  
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